Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
PHAR Pharming Group
11.760
+0.010+0.09%
Post Mkt Price
11.7600.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
151.92% 12.62M -57.26% 4M -91.11% 609K -58.40% 37.84M
Net income from continuing operations
921.81% 9.28M 166.07% 19.56M -65.88% 4.23M -51.38% 23.08M
Operating gains losses
442.56% 436K -3,889.36% -12.6M 504.50% 441K -74.25% -808K
Depreciation and amortization
-10.81% 1.95M -15.62% 2.07M 9.50% 2.19M 119.13% 19.61M
Other non cash items
42.49% -1.62M -135.18% -1.85M 75.09% -1.85M -124.55% -8.19M
Change In working capital
-21.97% 2.4M 78.39% -1.57M -183.51% -5.42M -52.26% -4.96M
-Change in receivables
-12.32% 4.05M 68.15% -1.43M -150.90% -1.46M 237.51% 5.92M
-Change in inventory
159.76% 423K -71.68% -4.32M -289.54% -2.3M -81.12% -6.15M
-Change in payables and accrued expense
-172.00% -2.33M 811.64% 4.25M 57.66% -1.65M -264.35% -5.19M
-Change in other working capital
1,406.29% 253K -119.14% -64K 93.56% -20K -63.60% 467K
Cash from discontinued investing activities
Operating cash flow
151.92% 12.62M -57.26% 4M -91.11% 609K -58.40% 37.84M
Investing cash flow
Cash flow from continuing investing activities
95.79% -298K 224.55% 6.4M 84.93% -375K -26.64% -21.31M
Capital expenditure reported
81.51% -342K 84.97% -521K 89.03% -208K -114.21% -10.74M
Net intangibles purchase and sale
130.55% 238K 48.37% -662K 82.90% -167K 47.83% -5.98M
Net business purchase and sale
-- -194K 2,064.82% 7.58M -- 0 -- 0
Net investment purchase and sale
-- -- -- -- -- 0 -- -4.59M
Net other investing changes
-- -- -- -- -- 1K -- --
Cash from discontinued investing activities
Investing cash flow
95.79% -298K 224.53% 6.39M 84.97% -374K -26.64% -21.31M
Financing cash flow
Cash flow from continuing financing activities
11.41% -1.92M 98.00% -451K -38.76% -2.89M -142.78% -27.95M
Net issuance payments of debt
1.19% -791K 25.76% -787K -50.30% -807K -103.58% -3.22M
Net common stock issuance
185.81% 818K -90.89% 288K -97.24% 18K 57.02% 4.72M
Cash dividends paid
-- 0 -- 0 -- 0 -- 0
Net other financing activities
-- -- -- -- -- -- 0.63% -25M
Cash from discontinued financing activities
Financing cash flow
11.41% -1.92M 97.98% -451K -24.97% -2.89M -142.78% -27.95M
Net cash flow
Beginning cash position
0.84% 189.96M -8.04% 189.67M -2.01% 191.92M 151.59% 205.16M
Current changes in cash
345.76% 10.4M 154.76% 9.94M -229.29% -2.65M -108.18% -11.41M
Effect of exchange rate changes
-378.57% -11.66M -260.30% -9.65M -95.16% 404K 88.26% -1.83M
End cash Position
2.94% 188.7M 0.84% 189.96M -8.04% 189.67M -6.60% 191.92M
Free cash flow
426.00% 12.51M -38.87% 2.82M -94.11% 234K -71.65% 21.13M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion with Explanation

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.
CEO: Dr. Sijmen (Simon) de Vries, M.D.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist